Ovarian stimulation and egg retrieval in the acutely ill patient: special considerations

This is a preview of subscription content, access via your institution.


  1. 1.

    Centers for Disease Control. A national action plan for cancer survivorship: advancing public health strategies. 2004 12/20/2018]; Available from: https://www.cdc.gov/cancer/survivors/pdf/plan.pdf.

  2. 2.

    Surveillance, epidemiology, and end results program. Cancer statistics and review 1975–2015. [cited 2018; Available from: http://www.seer.cancer.gov.

  3. 3.

    Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710–7.

    PubMed  Article  Google Scholar 

  4. 4.

    Ethics Committee of the American Society for Reproductive Medicine. Electronic address, A.a.o., Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. Fertil Steril, 2018. 110(3): p. 380–386.

  5. 5.

    Anazodo A, Ataman-Millhouse L, Jayasinghe Y, Woodruff TK. Oncofertility-an emerging discipline rather than a special consideration. Pediatr Blood Cancer. 2018;65(11):e27297.

    PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Ataman LM, Ma Y, Duncan FE, Uzzi B, Woodruff TK. Quantifying the growth of oncofertility. Biol Reprod. 2018;99(2):263–5.

    PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Letourneau JM, Sinha N, Wald K, Harris E, Quinn M, Imbar T, et al. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Hum Reprod. 2017;32(10):2123–9.

    PubMed  Article  Google Scholar 

  8. 8.

    Pecker LH, Maher JY, Law JY, Beach MC, Lanzkron S, Christianson MS. Risks associated with fertility preservation for women with sickle cell anemia. Fertil Steril. 2018;110(4):720–31.

    PubMed  Article  Google Scholar 

  9. 9.

    Ferschl MB, Tung A, Sweitzer BJ, Huo D, Glick DB. Preoperative clinic visits reduce operating room cancellations and delays. Anesthesiology. 2005;103(4):855–9.

    PubMed  Article  Google Scholar 

  10. 10.

    Reilly DF, McNeely MJ, Doerner D, Greenberg DL, Staiger TO, Geist MJ, et al. Self-reported exercise tolerance and the risk of serious perioperative complications. Arch Intern Med. 1999;159(18):2185–92.

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Subramani Y, Wong J, Nagappa M, Chung F. The benefits of perioperative screening for sleep apnea in surgical patients. Sleep Med Clin. 2017;12(1):123–35.

    PubMed  Article  Google Scholar 

  12. 12.

    Cartagena R. Preoperative evaluation of patients with obesity and obstructive sleep apnea. Anesthesiol Clin North Am. 2005;23(3):463–78 vi.

    PubMed  Article  Google Scholar 

  13. 13.

    Subramani Y, Nagappa M, Wong J, Mubashir T, Chung F. Preoperative evaluation: estimation of pulmonary risk including obstructive sleep apnea impact. Anesthesiol Clin. 2018;36(4):523–38.

    PubMed  Article  Google Scholar 

  14. 14.

    Devereaux PJ, Sessler DI. Cardiac complications in patients undergoing major noncardiac surgery. N Engl J Med. 2015;373(23):2258–69.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Bechard P, et al. Perioperative cardiorespiratory complications in adults with mediastinal mass: incidence and risk factors. Anesthesiology. 2004;100(4):826–34; discussion 5A.

    PubMed  Article  Google Scholar 

  16. 16.

    Grocott HP, Gulati H, Srinathan S, Mackensen GB. Anesthesia and the patient with pericardial disease. Can J Anaesth. 2011;58(10):952–66.

    PubMed  Article  Google Scholar 

  17. 17.

    Goh MH, Liu XY, Goh YS. Anterior mediastinal masses: an anaesthetic challenge. Anaesthesia. 1999;54(7):670–4.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Graetz T, N.D. Perioperative strategies to reduce bleeding and minimize transfusions. UpToDate. 2018; Available from: http://www.uptodate.com.

  19. 19.

    McCullough J. Overview of platelet transfusion. Semin Hematol. 2010;47(3):235–42.

    PubMed  Article  Google Scholar 

  20. 20.

    Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical practice guidelines from the AABB red blood cell transfusion thresholds and storage. Jama-J Am Med Assoc. 2016;316(19):2025–35.

    Article  Google Scholar 

  21. 21.

    Ye R, et al. Timing embryo preservation for a patient with high-risk newly diagnosed acute myeloid leukemia. Case Rep Hematol. 2018;2018:9807047.

    PubMed  PubMed Central  Google Scholar 

  22. 22.

    Meirow D, Epstein M, Lewis H, Nugent D, Gosden RG. Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod. 2001;16(4):632–7.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Brunicardi FC, et al. Schwartz’s principles of surgery. Tenth ed. New York: McGraw-Hill Education; 2014.

  24. 24.

    Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Howard SC, Trifilio S, Gregory TK, Baxter N, McBride A. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol. 2016;95(4):563–73.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Vormittag R, Simanek R, Ay C, Dunkler D, Quehenberger P, Marosi C, et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol. 2009;29(12):2176–81.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49(6):1404–13.

    PubMed  Article  Google Scholar 

  28. 28.

    Mahajan A, et al. The epidemiology of cancer-associated venous thromboembolism: an update. Semin Thromb Hemost. 2019.

  29. 29.

    Chan WS. The ‘ART’ of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol. 2009;21(3):207–18.

    PubMed  Article  Google Scholar 

  30. 30.

    Rova K, Passmark H, Lindqvist PG. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril. 2012;97(1):95–100.

    PubMed  Article  Google Scholar 

  31. 31.

    Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):92–128.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Gurunath S, Vinekar S, Biliangady R. Assisted reproductive techniques in a patient with history of venous thromboembolism: a case report and review of literature. J Hum Reprod Sci. 2018;11(2):193–7.

    PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Somigliana E, Peccatori FA, Filippi F, Martinelli F, Raspagliesi F, Martinelli I. Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation. Hum Reprod Update. 2014;20(6):944–51.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Practice Committee of the American Society for Reproductive Medicine. Electronic address, A.a.o. and M. Practice Committee of the American Society for reproductive, prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril, 2016. 106(7): p. 1634–1647.

  35. 35.

    Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E, Asch RH. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril. 1995;63(2):268–72.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Namavar Jahromi BM, et al. Ovarian hyperstimulation syndrome: a narrative review of its pathophysiology, risk factors, prevention, classification, and management. Iran J Med Sci. 2018;43(3):248–60.

    Google Scholar 

  37. 37.

    Claesson-Welsh L. Vascular permeability--the essentials. Ups J Med Sci. 2015;120(3):135–43.

    PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    Toftager M, Bogstad J, Bryndorf T, Løssl K, Roskær J, Holland T, et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod. 2016;31(6):1253–64.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Youssef MA, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev. (2011, 1):CD008046.

  40. 40.

    Anaya Y, Mata DA, Letourneau J, Cakmak H, Cedars MI, Rosen MP. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols (vol 35, pg 297, 2017). J Assist Reprod Genet. 2018;35(2):309–9.

Download references

Author information



Corresponding author

Correspondence to Kaitlyn Wald.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wald, K., Letourneau, J., Eshima-McKay, R. et al. Ovarian stimulation and egg retrieval in the acutely ill patient: special considerations. J Assist Reprod Genet 36, 2087–2094 (2019). https://doi.org/10.1007/s10815-019-01556-0

Download citation